System-Level Redesign of an Allogeneic Hematopoietic Cell Transplantation Program Associated with High 1-Year Survival and Reduced Cost.
Standardizing bone marrow transplant procedures dramatically improved survival rates and cut drug costs, demonstrating transformation's power.
Roswell Park implemented a comprehensive standardization initiative for its alloHCT program in 2024 (n=94 consecutive patients, median age 58.5 years; 54% HCT-CI ≥3), featuring post-transplant cyclophosphamide-based GVHD prophylaxis, fluid-sparing protocols, and an early outpatient discharge model. This yielded 1-year OS of 92.6%, NRM of 1%, and reduced pharmaceutical costs by 56%, highlighting operational standardization as a powerful, underutilized lever for improving alloHCT outcomes.
What the study was
- Study design
- cohort_study
- Category
- hematopoietic cell transplantation
- Maturity
- Validated
- Journal
- Transplantation and Cellular Therapy
Why it surfaced
Single-center cohort demonstrating that operational standardization alone—without new drugs—can achieve 1% NRM and 92.6% 1-year OS in alloHCT, rivaling best-in-class outcomes globally. 56% cost reduction is striking. From Brentjens/Davila/Betts group at Roswell Park.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.